The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Should we use melflufen to treat relapsed patients with poor prognosis?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Paul G. Richardson, Dana-Farber Cancer Institute, Boston, US. We asked, Should we use melflufen to treat relapsed patients with poor prognosis?

Richardson discusses promising data from the HORIZON trial evaluating melflufen, a highly lipophilic peptide-drug conjugate, in patients with relapsed/refractory myeloma. Richardson then discusses preliminary data from the ANCHOR study, evaluating melflufen in combination with dexamethasone, and either daratumumab or bortezomib, in patients with relapsed/refractory myeloma.


Share: